Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

丹诺医药
TENNOR THERAPEUTICS

TenNor Therapeutics (Suzhou) Limited
丹諾醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6872)

VOLUNTARY ANNOUNCEMENT
LATEST RESEARCH AND DEVELOPMENT PROGRESS OF CORE PRODUCTS RIFASUTENIZOL (TNP-2198) AND RIFAQUIZINONE (TNP-2092)

This announcement is made by TenNor Therapeutics (Suzhou) Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders and potential investors of the Company informed of the latest business developments of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that the Group's two core products, Rifasutenizol (TNP-2198) and Rifaquizinone (TNP-2092), have achieved multiple key research and development milestones, details of which are set out below.

Rifasutenizol (TNP-2198)

Rifasutenizol is the world's first new molecular entity ("**NME**") drug candidate developed to target *Helicobacter pylori* infection since the discovery of this pathogen in 1982. It features a unique synergistic dual-targeting mechanism of action: through the synergistic effect of inhibiting bacterial RNA polymerase to block the transcription process and producing free radicals through nitroreductase activation to destroy bacterial DNA and other components, it significantly enhances bactericidal efficacy, overcomes drug resistance, and significantly reduces the risk of resistance development.

The Company has completed seven clinical trials for rifasutenizol in China, including two Phase I clinical trials, two clinical pharmacology trials, two Phase II clinical trials and one Phase III clinical trial. Early-phase clinical data on rifasutenizol were published in The Lancet Infectious Diseases in 2024 as one of the featured articles, attracting global attention. The results of the Phase III clinical trial of rifasutenizol were also published in The Lancet Infectious Diseases on 11 September 2025. In addition, the Company presented the latest research findings on rifasutenizol at the 2025 Digestive Disease Week conference in the U.S., which is the world's largest international conference in the field of gastrointestinal diseases, and the presentation was selected as a Distinguished Plenary Presentation.

Recognizing its potential in treating *Helicobacter pylori* infection that may lead to severe and life-threatening conditions, the United States Food and Drug Administration has granted rifasutenizol the Qualified Infectious Disease Product designation.

The Company submitted drug marketing registration applications for rifasutenizol capsules to the National Medical Products Administration of the PRC (the "**NMPA**") in August 2025, and received a supplementary information notice issued by the Center for Drug Evaluation of the NMPA in June 2026. As of the date of this announcement, the submission of all supplementary information in respect of rifasutenizol has been completed.

We may not be able to ultimately market rifasutenizol for the treatment of *Helicobacter pylori* infection, and develop and market rifasutenizol for the treatment of bacterial vaginosis and *Clostridioides difficile* infection successfully.

Rifaquizinone (TNP-2092)

Rifaquizinone is the world's first new drug candidate developed specifically to target the significant unmet clinical need for biofilm infections associated with implantable medical devices through a triple-targeting mechanism of action. Through its unique triple-targeting synergistic mechanism of action by simultaneously inhibiting bacterial RNA polymerase, DNA gyrase and DNA topoisomerase IV, rifaquizinone not only demonstrates potent bactericidal activity against drug-resistant pathogens (including methicillin-resistant S. aureus and quinolone-resistant S. aureus), but also reduces the resistance frequency to an extremely low level ($<10^{-12}$).

In the preclinical study, rifaquizinone has demonstrated strong *in vitro* and *in vivo* biofilm bactericidal activity, and its efficacy is significantly superior to that of current standard-of-care antibiotics. The Company has successfully completed six Phase I and Phase II clinical trials in the U.S. and China, and the intravenous administration of rifaquizinone has demonstrated favorable safety and excellent efficacy profile in the treatment of acute bacterial skin and skin structure infections ("**ABSSSI**"). Indications under development include: prosthetic joint infection ("**PJI**"), ABSSSI and left ventricular assist device infection ("**LVADI**") treated by intravenous or intra-articular ("**IA**") administration.

The transformative potential of rifaquizinone has been highly recognized by regulatory authorities. Rifaquizinone has been granted Qualified Infectious Disease Product, Fast Track, and Orphan Drug designations by the United States Food and Drug Administration. In addition, rifaquizinone has also received the outstanding award at the National Disruptive Technology Innovation Competition in China (中國全國顛覆性技術創新大賽優勝獎).

As of the date of this announcement, the Company has selected the treatment of PJI via IA administration as the core indication of rifaquizinone for prioritized development. Positive results were obtained from the Phase IIa proof-of-concept clinical trial of rifaquizinone via IA administration for the treatment of PJI as an alternative to surgery, and the multi-center Phase IIb clinical trial has also completed the enrollment of the first patient. This trial is designed to further evaluate the efficacy, safety and pharmacokinetic profile of rifaquizinone in the treatment of PJI without debridement or revision surgery, marking that this potentially disruptive therapy has entered a key stage of clinical development.

We may not be able to ultimately develop and market rifaquizinone successfully.

About the Company

The Company is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet clinical needs in disease areas associated with bacterial infections and bacterial metabolism. Relying on its proprietary multi-targeting conjugate molecule technology platform, the Company aims to deliver therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes.

As of the date of this announcement, the Company had established a drug research and development pipeline comprising eight innovative programs, including two core products, namely: rifasutenizol (TNP-2198), a multi-targeting conjugated NME candidate for the treatment of *Helicobacter pylori* infection when used in combination with amoxicillin and a proton pump inhibitor, as well as monotherapy for bacterial vaginosis and *Clostridioides difficile* infection; and rifaquizinone (TNP-2092) injection, a triple-targeting NME candidate for the treatment of ABSSSI and implant-associated bacterial infections (such as PJI, LVADI and catheter-related bloodstream infection).

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
TenNor Therapeutics (Suzhou) Limited
Dr. Ma Zhenkun
Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager

Hong Kong, 12 November 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ma Zhenkun as an executive Director; (ii) Dr. Song Gaoguang as a non-executive Director; and (iii) Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping as independent non-executive Directors.